非酒精性脂肪性肝病患者血清脂联素、维生素D和载脂蛋白B水平变化及其临床意义探讨*

doi:10.3969/j.issn.1672-5069.2023.02.010

摘要/Abstract

摘要： 目的探讨非酒精性脂肪性肝病(NAFLD)患者血清脂联素(APN)、25-羟维生素D[25]-(OH)D]和载脂蛋白B(ApoB)水平变化及其临床意义。方法 2018年8月～2021年5月我院诊治的NAFLD患者117例和健康体检者51例,使用Fibroscan行肝脏硬度检测(LSM)和受控衰减参数(CAP)检查。采用化学发光法检测血清25-(OH)D水平,采用ELISA法检测血清APN和ApoB水平。结果本组NAFLD患者包括单纯性脂肪肝组37例、非酒精性脂肪性肝炎(NASH)58例和脂肪性肝硬化22例;根据LSM水平,无肝纤维化81例和进展期肝纤维化36例;NAFLD组血清APN和25-(OH)D水平分别为(9.7±1.9)μg/mL和(30.8±6.4)nmol/L,显著低于健康人【分别为(12.9±2.7)μg/mL和(57.9±8.1)nmol/L,P<0.05】,而血清ApoB水平为(1.2±0.2)g/L,显著高于健康人【(0.7±0.1)g/L,P<0.05】;脂肪性肝硬化组血清APN和25-(OH)D水平分别为(7.9±1.3)μg/mL和(24.3±6.9)nmol/L,显著低于NASH组【分别为(9.2±2.1)μg/mL和(30.5±7.4)nmol/L,P<0.05】或单纯性脂肪肝组【分别为(11.5±2.5)μg/mL和(35.1±7.1)nmol/L,P<0.05】,而血清ApoB水平为(1.5±0.2)g/L,显著高于NASH组【((1.3±0.3)g/L,P<0.05】或单纯性脂肪肝组【(0.9±0.1)g/L,P<0.05】;进展期肝硬化患者血清APN和25-(OH)D水平分别为(8.1±1.4)μg/mL和(25.3±6.7)nmol/L,显著低于无肝纤维化患者【分别为(10.4±2.2)μg/mL和(33.2±7.5)nmol/L,P<0.05】,而血清ApoB水平为(1.6±0.3)g/L,显著高于无肝纤维化患者【(1.0±0.2)g/L,P<0.05】。结论 NAFLD患者存在血清APN、25-(OH)D和ApoB异常变化,监测这些变化可能有助于判断病情,值得进一步研究。

关键词: 非酒精性脂肪性肝病, 脂联素, 维生素D, 载脂蛋白B, 临床意义

Abstract: Objective The aim of this study was to explore the implication of serum adiponectin (APN), 25-hydroxyvitamin D [25-(OH)D] and apolipoprotein B (ApoB) level changes in patients with nonalcoholic fatty liver disease (NAFLD). Methods A total of 117 patients with NAFLD and 51 healthy individuals were enrolled in our hospital between August 2018 and May 2021, and all underwent liver stiffness measurement (LSM) by Fibroscan. Serum 25-(OH)D level was detected by chemiluminescence, and serum APN and ApoB levels were detected by ELISA. Results Based on the controlled attenuated parameters (CAP), the simple fatty liver (SFL) was found in 37 cases, the non-alcoholic steatohepatitis (NASH) was found in 58 cases and the fatty liver-induced cirrhosis was found in 22 cases, and out of them, no liver fibrosis was determined in 81 patients with NAFLD and progressive liver fibrosis in 36 cases; serum APN and 25-(OH)D levels in patients with NAFLD were (9.7±1.9)μg/mL and (30.8±6.4)nmol/L, both significantly lower than [(12.9±2.7)μg/mL and (57.9±8.1)nmol/L, respectively, P<0.05], while serum ApoB level was (1.2±0.2)g/L, significantly higher than [(0.7±0.1)g/L, P<0.05] in healthy persons; serum APN and 25-(OH)D levels in patients with cirrhosis were (7.9±1.3)μg/mL and (24.3±6.9)nmol/L, both significantly lower than [(9.2±2.1)μg/mL and (30.5±7.4)nmol/L, respectively, P<0.05] in patients with NASH or [(11.5±2.5)μg/mL and (35.1±7.1)nmol/L, respectively, P<0.05] in patients with SFL, while serum ApoB level was (1.5±0.2)g/L, significantly higher than [((1.3±0.3)g/L, P<0.05] in patients with NASH or [(0.9±0.1)g/L, P<0.05] in patients with SFL; serum APN and 25-(OH)D levels in patients with progressive liver fibrosis were (8.1±1.4)μg/mL and (25.3±6.7)nmol/L, both significantly lower than [(10.4±2.2)μg/mL and (33.2±7.5)nmol/L, P<0.05], while serum ApoB level was (1.6±0.3)g/L, significantly higher than [(1.0±0.2)g/L, P<0.05] in patients without liver fibrosis. Conclusion Serum APN, 25-(OH)D and ApoB levels are abnormal in patients with NAFLD, which might help predict the disease severity and the progression of liver fibrosis.

Key words: Nonalcoholic fatty liver disease, Adiponectin, Vitamin D, Apolipoprotein B, Implication

郝蕾, 高卫东, 胡娟娟, 张琳, 邢亚恒. 非酒精性脂肪性肝病患者血清脂联素、维生素D和载脂蛋白B水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 189-192.

Hao Lei, Gao Weidong, Hu Juanjuan, et al.. Changes of serum adiponectin, vitamin D and apolipoprotein B levels in patients with nonalcoholic fatty liver disease[J]. Journal of Practical Hepatology, 2023, 26(2): 189-192.

参考文献

[1] 张枫, 阎妍. 非酒精性脂肪性肝病患者血清载脂蛋白B水平及其临床意义探讨. 实用肝脏病杂志, 2019, 22(1): 61-64.
[2] Bril F, McPhaul MJ, Kalavalapalli S, et al. Intact fasting insulin identifies nonalcoholic fatty liver disease in patients without diabetes. J Clin Endocrinol Metab, 2021, 106(11): e4360-e4371.
[3] Yilmaz Y, Eren F. Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology. Eur J Gastroenterol Hepatol, 2019, 31(1): 43-46.
[4] Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology, 2019, 156( 5): 1264-1281.
[5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪肝专家委员会. 非酒精性脂肪性肝病防治指南 (2018年版). 实用肝脏病杂志, 2018, 21(2): 177-186.
[6] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版). 中华肝脏病杂志, 2010, 18(3): 163-166.
[7] El-Ashmawy HM, Ahmed AM. Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes. Eur J Gastroenterol Hepatol, 2019, 31(7): 859-864.
[8] Hussain M, Iqbal J, Malik SA, et al. Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients. Pak J Pharm Sci, 2019, 32(3 Special): 1343-1348.
[9] 徐亮, 江勇, 范建高, 等. 反应性氧化物, 脂联素在慢性乙型肝炎病毒感染合并非酒精性脂肪性肝病中的研究. 中华肝脏病杂志, 2020, 28(3): 247-253.
[10] 方菊梅, 张万里, 陈怡发, 等. 非酒精性脂肪性肝炎患者血清sCD163和IL-1βmRNA水平变化及其临床意义探讨. 实用肝脏病杂志, 2020, 23(3): 368-371.
[11] Karrar A, Hariharan S, Fazel Y, et al. Analysis of human leukocyte antigen allele polymorphism in patients with non alcoholic fatty liver disease. Medicine, 2019, 98(32): e16704.
[12] 陈丽丽, 符茂雄, 刘正金, 等. 非酒精性脂肪性肝炎患者血清成纤维细胞生长因子-21和脂联素水平变化及其临床意义探讨. 实用肝脏病杂志, 2020, 23(5): 658-661.
[13] Sun X, Chen R, Yan G, et al. Gender-specific associations between apolipoprotein A1 and arterial stiffness in patients with nonalcoholic fatty liver disease. Peer J, 2020, 8(19): e9757.
[14] Gharekhani A, Najafipour F, Baradaran H, et al. The effect of treating vitamin D deficiency or insufficiency on serum adiponectin, leptin and insulin resistance of type 2 diabetes mellitus patients: A pilot study. Iran J Pharm Res, 2020, 19(3): 86-94.
[15] Rafiq R, El Haddaoui H, de Mutsert R, et al. Adiposity is a confounding factor which largely explains the association of serum vitamin D concentrations with C-reactive protein, leptin and adiponectin. Cytokine, 2020, 131(6): e155104.
[16] Onoue T, Goto M, Wada E, et al. Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial. PLoS One, 2020, 15(1): e0228004.
[17] Jansson-Knodell CL, Gawrieh S, McIntyre AD, et al. Apolipoprotein B and PNPLA3 double heterozygosity in a father-Son pair with advanced nonalcoholic fatty liver disease. Hepatology, 2020, 71(1): 383-385.
[18] Rahmanabadi A, Mahboob S, Amirkhizi F, et al. Oral α-lipoic acid supplementation in patients with non-alcoholic fatty liver disease: Effects on adipokines and liver histology features. Food Funct, 2019, 10(8): 4941-4952.
[19] Huang H, Wang J, Xu L, et al. Association between high-density lipoprotein cholesterol to apolipoprotein A-I ratio and nonalcoholic fatty liver disease: A cross-sectional study. Int J Endocrinol, 2021, 21(6): e6676526.
[20] Li BT, Sun M, Li YF, et al. Disruption of the ERLIN-TM6SF2-APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease. PLoS Genetics, 2020, 16(8): e1008955.
[21] van den Berg EH, Corsetti JP, Bakker SJL, et al. Plasma ApoE elevations are associated with NAFLD: The PREVEND Study. PLoS One, 2019, 14(8): e0220659.
[22] Machado MV, Policarpo S, Coutinho J, et al. What is the role of the new index relative fat mass (RFM) in the assessment of nonalcoholic fatty liver disease (NAFLD)? Obes Surg, 2020, 30(4): 1-9.
[23] Shabalala SC, Dludla PV, Mabasa L, et al. The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling. Biomed Pharmacother, 2020, 131(11): e110785.

非酒精性脂肪性肝病患者血清脂联素、维生素D和载脂蛋白B水平变化及其临床意义探讨^*

Changes of serum adiponectin, vitamin D and apolipoprotein B levels in patients with nonalcoholic fatty liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	魏丽, 刘博, 赵楠, 梁丽君. 恩替卡韦抗病毒治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者病毒学应答情况分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 181-184.
[2]	范明芳, 田瑛, 周倩, 接贵涛, 刘淑芳. 慢性丙型肝炎合并非酒精性脂肪性肝病患者血清RBP4和SREBP-1c水平变化分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 185-188.
[3]	方颖, 金家东, 汪芾, 周达. 新冠疫情期间情绪对非酒精性脂肪性肝病患者血生化指标的影响^*[J]. 实用肝脏病杂志, 2023, 26(2): 193-196.
[4]	刘岗, 张浩, 胡峻. 非酒精性脂肪性肝病患者血清miR-183-5p和miR-96-5p水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 197-201.
[5]	李潇萌, 吴少玉, 王媛媛. 非酒精性脂肪性肝病合并2型糖尿病患者血清同型半胱氨酸、成纤维细胞生长因子21和核因子-κB水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 202-205.
[6]	黄淡霞, 招志辉, 萧月兴, 何艳青. 小檗碱通过调节肠道菌群改善高脂饮食诱导的非酒精性脂肪性肝病大鼠肝组织炎症实验研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 23-26.
[7]	陈凤莲, 朱青蓝, 朱伶俐, 陈国飞. 非酒精性脂肪性肝病患者外周血恒定自然杀伤T细胞和CD4⁺/CD8⁺T细胞活化差异研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 31-34.
[8]	徐伟强, 刘淑萍, 李潇萌. 体检人群非酒精性脂肪性肝病检出率及其危险因素分析^*[J]. 实用肝脏病杂志, 2023, 26(1): 35-38.
[9]	王浩宇, 周娟燕, 刘茹, 徐菁, 马少君. 自身免疫性肝炎患者外周血NKp46⁺ILC3细胞和Th17细胞变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(1): 39-42.
[10]	林仕文, 韩锋, 魏玉, 陈文传. 药物性肝损伤患者血清miR-21和miR-124a水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(1): 43-46.
[11]	陈怡, 朱友, 周希乔. 甲状腺激素与非酒精性脂肪性肝病研究进展^*[J]. 实用肝脏病杂志, 2023, 26(1): 145-148.
[12]	李向阳, 丁光伟, 靳铭. 恩替卡韦治疗慢性乙型肝炎合并NAFLD患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 776-779.
[13]	孙峥, 王笑烨, 袁景, 梁丽. 达格列净联合利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者短期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 796-799.
[14]	蔡勇, 李璟, 欧琴. 2型糖尿病合并非酒精性脂肪性肝病患者血清网膜素、视黄醇结合蛋白4和Ⅰ型原胶原氨基端前肽水平及意义分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 800-803.
[15]	孙凌, 杭玮, 邓国忠. 二甲双胍联合吡格列酮治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 804-807.